E-slide Library

Defining and assessing treatment targets for ulcerative colitis

Tauseef Ali, MD, FACP, FACG

IBD Center Director
Assistant Professor
University of Oklahoma Medical Center
Oklahoma City, OK



The primary goal of ulcerative colitis treatment is to induce and maintain clinical remission, with therapeutic decision-making driven by the presence or absence of clinical symptoms. Monitoring for objective evidence of inflammation using endoscopy or laboratory biomarkers may be useful for measuring disease activity. This Case Consult discusses treatment goals and targets in ulcerative colitis, and the role that various biomarkers play in assessment.

This activity has been designed to meet the educational needs of gastroenterologists and registered nurses involved in the care of patients with inflammatory bowel disease (IBD).

Release date: May 11, 2015

Learning objectives

After completing this activity, the participant should be better able to:

  • Summarize relevant treatment goals and targets for ulcerative colitis
  • Describe the role of biomarkers and histology in assessing treatment response in ulcerative colitis
  • Provide appropriate care and counsel for patients and their families.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

View Presentation